BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 21, 2002
View Archived Issues
IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma
IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today)
Read More
Fresh From Mergers, Buyouts, CEOs Mull Boons And Pitfalls
Read More
Pseudomonas aeruginosa, Lethal Cystic Fibrosis Scourge, Trades Surprise Blows With Scientists
Read More
Avant Dropping TP10 Following Phase II Failure; Stock Tumbles
Read More
Other News To Note
Read More
Bush Might Have Final Say On Biotech’s Role In Bioterrorism
Read More
Anadys, Structural GenomiX Form Antibacterials Alliance
Read More